In This Section      
 

Search Results

A total of 44 matching records were found.

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10070
Phase 1/2 study of navitoclax plus vistusertib in patients with relapsed small cell lung cancer (SCLC) and other solid tumors (ETCTN10070)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10131
A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel (ETCTN10131)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J11143
Multiparametric MRI for assessing radiotherapy treatment response of prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

J1409
Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer (Karmanos Cancer Institute protocol # 2013-108)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J14106
Non-invasive Detection of Cancer DNA in Blood and Urine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1416
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1454
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15106
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15119
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7–Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15203
Pilot Biomarker Study of Stereotactic Body Radiation Therapy for Prostate Cancer Oligometastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1557
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1560
Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk localized and Locally Advanced Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16107
Partnering Around Cancer Clinical Trials (PACCT)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16131
A Phase 1b Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) (Sponsor Protocol c15-160)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1615
A Phase 1/2 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors (Sponsor Protocol Number: D419NC00001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1618
A phase II study of definitive therapy for newly diagnosed men with oligometastatic prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1619
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1693
Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate and High-Risk Prostate Cancer – a Pilot and Biomarker Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17121
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17122
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms (CP-MGD013-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17140
A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC) (GSK 204697).

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17149
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men with an Elevated PSA

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17187
Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17197
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer (Protocol 1205-201)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1778
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors (sponsor protocol MS100015-0019)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1812
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer [COMBAT-CRPC]

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18127
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients with Metastatic Prostate Cancer – an Interscan Variability and Intraobserver Agreement Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1850
Biomarker Detection in Men with Relapsed Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1851
Randomized trial assessing induction of double strand breaks with androgen receptor partial agonist in patients on androgen suppression

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1863
Study of 18F-DCFPyL PET/CT, for detection of radiological progression in patients with metastatic (M+) and non-metastatic (M0) castration resistant prostate cancer receiving standard androgen receptor targeted treatment

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1883
A Phase 2 Non-randomized Open-label Study Examining the Effect of eFT508 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC) (eFT508-0009)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNEA8153
EA8153 Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNS1802
S1802 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore